CD47 and neoplasm: Considering the clinical limitations of current CAR-T cell therapy in the treatment of solid cancers, the combination strategy of CAR-M cell therapy with oAd-CD47 may be an effective approach for personalized tumor-specific oncolytic immunotherapy.